Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Share:
Related MDCO
The Medicines Company Is A Top Pick For 2017
18 Stocks Moving In Friday's Pre-Market Session
Related BMY
Mid-Afternoon Market Update: Skyworks Surges After Strong Earnings Report; Affimed Shares Drop
15 Biggest Mid-Day Losers For Friday
Alphabet, Microsoft, Boeing, Starbucks Lead Investing Action Plan (Investor's Business Daily)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News

 

Related Articles (MDCO + BMY)

View Comments and Join the Discussion!